LENSAR Inc (LNSR) - Total Liabilities
Based on the latest financial reports, LENSAR Inc (LNSR) has total liabilities worth $82.33 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore LENSAR Inc net asset momentum to track the company's year-over-year net asset growth rate.
LENSAR Inc - Total Liabilities Trend (2018–2024)
This chart illustrates how LENSAR Inc's total liabilities have evolved over time, based on quarterly financial data. See LENSAR Inc free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.
LENSAR Inc Competitors by Total Liabilities
The table below lists competitors of LENSAR Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Fy Grp Ltd
TW:6807
|
Taiwan | NT$1.05 Billion |
|
TEAM INC. DL-30
F:T9CA
|
Germany | €509.93 Million |
|
Largo Resources Ltd
TO:LGO
|
Canada | CA$182.22 Million |
|
Thai Wacoal Public Company Limited
BK:WACOAL
|
Thailand | ฿927.57 Million |
|
ALT Telecom Public Company Limited
BK:ALT
|
Thailand | ฿2.54 Billion |
|
Cactus Acquisition Corp 1 Ltd
NASDAQ:CCTS
|
USA | $2.27 Million |
|
LTR Pharma Ltd
AU:LTP
|
Australia | AU$457.81K |
|
OKYO Pharma Ltd ADR
NASDAQ:OKYO
|
USA | $8.06 Million |
Liability Composition Analysis (2018–2024)
This chart breaks down LENSAR Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see LNSR company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.24 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -6.79 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.17 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how LENSAR Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for LENSAR Inc (2018–2024)
The table below shows the annual total liabilities of LENSAR Inc from 2018 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $47.65 Million | +112.64% |
| 2023-12-31 | $22.41 Million | +61.68% |
| 2022-12-31 | $13.86 Million | +19.63% |
| 2021-12-31 | $11.59 Million | -2.72% |
| 2020-12-31 | $11.91 Million | -81.70% |
| 2019-12-31 | $65.09 Million | +31.89% |
| 2018-12-31 | $49.35 Million | -- |
About LENSAR Inc
LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism in the United System. The company offers LENSAR Laser System which incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcom… Read more